Dimethicone

Summary

Dimethicone (CHEMBL2108200) is an approved unknown (ATC P03AX05); indicated across 9 conditions including parasitic infectious disease and sunburn.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Unknown
• ATC class: P03AX05
• Indications: 9 conditions
• Clinical trials: 2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2108200
Name	Dimethicone
Type	Unknown
Max phase	4
ATC	P03AX05

Also known as: Conotrane, Cymex, Dimethicone, Dimethicone 360, Dimethicone component of simethicone, Dimethicone medical fluid 360, unspecified, Dimethicones, Dimethyl polysiloxane, Dimethylpolysiloxane, Dimethylsilicone fluid, Dimeticona

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

9 indications (8 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
parasitic infectious disease	4	MONDO:0005135	EFO:0001067
sunburn	4	MONDO:0005326	EFO:0003958
dermatitis	4	MONDO:0002406	MONDO:0002406
skin neoplasm	4	MONDO:0002531	MONDO:0002898
ulcer disease	4	MONDO:0043839	MONDO:0043839
psoriasis	2	MONDO:0005083	EFO:0000676

3 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
PHASE2	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01914627	PHASE2	COMPLETED	Parallel Group Trial to Evaluate the Efficacy and Safety of Loion® Compared to 10% Salicylic Acid in Patients With Chronic Psoriasis Capitis
NCT06713421	Not specified	RECRUITING	Effect of Premedication With Pronase on Mucosal Cleanliness During EGD

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).